| Overview |
| bs-11299R-Cy5.5 |
| NAB2/MADER Polyclonal Antibody, Cy5.5 Conjugated |
| WB |
| Mouse |
| Human, Rat, Dog, Cow, Sheep, Pig, Horse, Rabbit |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human NAB2 |
| 221-320/525 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Nucleus |
| EGR 1 binding protein 2; EGR-1-binding protein 2; EGR1 binding protein 2; MADER; Melanoma associated delayed early response protein; Melanoma-associated delayed early response protein; MGC75085; Nab 2; nab2; NAB2_HUMAN; NGFI A binding protein 2 EGR1 binding protein 2; NGFI A binding protein 2; NGFI-A-binding protein 2; Protein MADER. |
| Transcriptional control is in part regulated by interactions between DNA-bound transcription factors, such as Egr-1/NGFI-A, and coregulatory proteins, such as NAB (for NGFI-A-binding proteins). The evolutionarily conserved NAB proteins, NAB1 and NAB2 are corepressors of EGF-1/NGFI-A. Both NAB1 and NAB2 contain an amino terminal NAB conserved domain 1 (NCB1), which is required for binding NGFI-A, and a carboxy terminal NCD2 domain, which is responsible for the repressor function of NAB proteins. NAB2 is principally localized in the nucleus and may play a role in the downregulation of NGFI-A activity as well as in controlling fundamental processes such as cell division, differentiation and apoptosis. NAB2 localizes to chromosome 12q13.3-14.1, a region that is rearranged in several solid tumors, lipomas, and liposarcomas. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz